Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.

Chang, Nakho; Lee, Hye Won; Lim, Joung Eun; Jeong, Da Eun; Song, Hye Jin; Kim, Sudong; Nam, Do-Hyun; Sung, Hyun Hwan; Jeong, Byong Chang; Seo, Seong Il; Jeon, Seong Soo; Lee, Hyun Moo; Choi, Han-Yong; Jeon, Hwang Gyun

Chang, Nakho; Lee, Hye Won; Lim, Joung Eun; Jeong, Da Eun; Song, Hye Jin; Kim, Sudong; Nam, Do-Hyun; Sung, Hyun Hwan; Jeong, Byong Chang; Seo, Seong Il; Jeon, Seong Soo; Lee, Hyun Moo; Choi, Han-Yong; Jeon, Hwang Gyun.

Chang N; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, Korea.
Lee HW; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Lim JE; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul 06351, Korea.
Jeong DE; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul 06351, Korea.
Song HJ; Institute for Future Medicine, Samsung Medical Center, Seoul 06351, Korea.
Kim S; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Nam DH; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, Korea.
Sung HH; Department of Anatomy and Cell Biology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Jeong BC; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul 06351, Korea.
Seo SI; Samsung Advanced Institute of Technology, Samsung Electronics Co., Ltd., Seoul 06351, Korea.
Jeon SS; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, Korea.
Lee HM; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Choi HY; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul 06351, Korea.
Jeon HG; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.

Oncotarget ; 7(32): 51626-51639, 2016 08 09.

Article en En | MEDLINE | ID: mdl-27438149

Asunto(s)

Antineoplásicos/farmacología; Carcinoma de Células Transicionales/patología; Dasatinib/farmacología; Ensayos de Selección de Medicamentos Antitumorales/métodos; Receptores ErbB/genética; Fosfohidrolasa PTEN/genética; Neoplasias de la Vejiga Urinaria/patología; Antineoplásicos/uso terapéutico; Carcinoma de Células Transicionales/tratamiento farmacológico; Carcinoma de Células Transicionales/genética; Línea Celular Tumoral; Dasatinib/uso terapéutico; Amplificación de Genes; Eliminación de Gen; Humanos; Masculino; Persona de Mediana Edad; Neoplasias de los Músculos/tratamiento farmacológico; Neoplasias de los Músculos/genética; Neoplasias de los Músculos/secundario; Mutación; Invasividad Neoplásica; Cultivo Primario de Células/métodos; Neoplasias de la Vejiga Urinaria/tratamiento farmacológico; Neoplasias de la Vejiga Urinaria/genética

Palabras clave

EGFR; PTEN; drug screening; muscle invasive bladder cancer; patient-derived xenograft

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Ensayos de Selección de Medicamentos Antitumorales / Carcinoma de Células Transicionales / Fosfohidrolasa PTEN / Receptores ErbB / Dasatinib / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google